SynthesisInternational journal of molecular sciences2022
Platelet-Rich Plasma as an Alternative to Xenogeneic Sera in Cell-Based Therapies: A Need for Standardization.
Synthesis in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cellularized Skin Substitute Bioengineering for Regenerative Medicine: Cell Sources, Culture Strategies, and Transition Toward Defined, Xeno-Free Culture Systems.Advanced healthcare materials · 2026Review
- Platelet-rich plasma enhances post-conditioning recovery from testicular ischemia-reperfusion injury: a novel experimental approach.Scientific reports · 2026Article
- Platelet-Rich Plasma and Stem Cell Therapies for Musculoskeletal Rehabilitation: Current Evidence on Dosing, Activation, and Functional Performance.Orthopedic reviews · 2026Article
- Standardization of canine platelet-rich plasma preparation and its functional characterization.Journal of veterinary science · 2026Article
- Applications of bone regenerative medicine in the foot and ankle: mechanisms, technologies, and therapeutic advances.Frontiers in bioengineering and biotechnology · 2025Review
- Impact of increasingly complex cell culture conditions on the proteome of human periodontal ligament stem cells.Regenerative medicine · 2025Article
- The Biological Effect of Enriching the Plasma Content in Platelet-Rich Plasma: An In Vitro Study.Biomolecules · 2024Article
- Platelet-Rich Plasma Promotes the Expansion of Human Myoblasts and Favors the In Vitro Generation of Human Muscle Reserve Cells in a Deeper State of Quiescence.Stem cell reviews and reports · 2024Article
- Quality management overview for the production of a tissue-engineered human skin substitute in Malaysia.Stem cell research & therapy · 2023Review
- Adjunctive Plasma Rich in Growth Factors in the Treatment of Osteomyelitis and Large Odontogenic Cysts Prior to Successful Implant Rehabilitation: Case Report.Dentistry journal · 2023Article
- Swiss Medical Devices for Autologous Regenerative Medicine: From Innovation to Clinical Validation.Pharmaceutics · 2022Review
- The role of allogeneic platelet-rich plasma in patients with diabetic foot ulcer: Current perspectives and future challenges.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
There has been an explosion in scientific interest in using human-platelet-rich plasma (PRP) as a substitute of xenogeneic sera in cell-based therapies. However, there is a need to create standardization in this field. This systematic review is based on literature searches in PubMed and Web of Science databases until June 2021. Forty-one studies completed the selection criteria. The composition of PRP was completely reported in less than 30% of the studies. PRP has been used as PRP-derived supernatant or non-activated PRP. Two ranges could be identified for platelet concentration, the first between 0.14 × 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.